Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IMDX Insight Molecular Diagnostics Inc.
- Stocks
- Healthcare
- NASDAQ: IMDX
Price (delayed)
$2.93
Market cap
$83.8M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.9
Enterprise value
$54.54M
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular
Highlights
The revenue has soared by 178% YoY and by 104% QoQ
Insight Molecular Diagnostics's gross profit has surged by 173% QoQ
Insight Molecular Diagnostics's equity has surged by 183% QoQ but it has decreased by 12% YoY
Insight Molecular Diagnostics's net income has decreased by 43% YoY but it has increased by 4.4% QoQ
Key stats
What are the main financial stats of IMDX
Market
Valuations
Earnings
Shares outstanding
28.6M
Market cap
$83.8M
Enterprise value
$54.54M
Price to earnings (P/E)
N/A
Price to book (P/B)
8.2
Price to sales (P/S)
19.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.19
Revenue
$3.84M
Gross profit
$2.02M
Operating income
-$58.57M
Net income
-$58.26M
EBIT
-$58.16M
EBITDA
-$56.44M
Free cash flow
-$23.54M
Per share
Balance sheet
Liquidity
EPS
-$3.9
EPS diluted
-$3.9
Free cash flow per share
-$0.92
Book value per share
$0.36
Revenue per share
$0.15
TBVPS
$1.78
Total assets
$60.36M
Total liabilities
$50.14M
Debt
$3.48M
Equity
$10.22M
Working capital
$26.58M
Debt to equity
0.34
Current ratio
3.75
Quick ratio
3.75
Net debt/EBITDA
0.52
Margins
Efficiency
Dividend
EBITDA margin
-1,468.7%
Gross margin
52.6%
Net margin
-1,516.1%
Operating margin
-1,524.1%
Return on assets
-97%
Return on equity
-767.7%
Return on invested capital
-1,131.6%
Return on capital employed
-114.8%
Return on sales
-1,513.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMDX stock price
How has the Insight Molecular Diagnostics stock price performed over time
Intraday
2.45%
1 week
-3.3%
1 month
10.57%
1 year
-12.01%
YTD
23.11%
QTD
-2.98%
Financial performance
How have Insight Molecular Diagnostics's revenue and profit performed over time
Revenue
$3.84M
Gross profit
$2.02M
Operating income
-$58.57M
Net income
-$58.26M
Gross margin
52.6%
Net margin
-1,516.1%
The revenue has soared by 178% YoY and by 104% QoQ
Insight Molecular Diagnostics's gross profit has surged by 173% QoQ
IMDX's gross margin has surged by 62% year-on-year and by 34% since the previous quarter
The operating margin has soared by 53% QoQ and by 48% YoY
Price vs fundamentals
How does IMDX's price correlate with its fundamentals
Growth
What is Insight Molecular Diagnostics's growth rate over time
Valuation
What is Insight Molecular Diagnostics stock price valuation
P/E
N/A
P/B
8.2
P/S
19.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.19
The company's EPS rose by 23% YoY and by 16% QoQ
The stock's price to book (P/B) is 196% more than its 5-year quarterly average of 2.7
Insight Molecular Diagnostics's equity has surged by 183% QoQ but it has decreased by 12% YoY
The revenue has soared by 178% YoY and by 104% QoQ
The price to sales (P/S) is 71% less than the 5-year quarterly average of 65.5 and 41% less than the last 4 quarters average of 32.3
Efficiency
How efficient is Insight Molecular Diagnostics business performance
IMDX's return on assets has dropped by 87% year-on-year
The company's return on sales has surged by 53% QoQ and by 49% YoY
IMDX's ROIC is up by 26% since the previous quarter but it is down by 16% year-on-year
Dividends
What is IMDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMDX.
Financial health
How did Insight Molecular Diagnostics financials performed over time
IMDX's total assets is 20% greater than its total liabilities
The current ratio has soared by 131% from the previous quarter
IMDX's quick ratio has surged by 129% since the previous quarter
IMDX's debt is 66% smaller than its equity
Insight Molecular Diagnostics's equity has surged by 183% QoQ but it has decreased by 12% YoY
The debt to equity is up by 17% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.